DETROIT – Researchers at Henry Ford Hospital compared the patient population of a major U.S. prostate cancer study with patients found in three U.S. cancer databases, ultimately finding the patients of the study to be inconsistent with the average prostate cancer patient. The researchers found the patients of the Prostate Cancer Intervention versus Observation Trial (PIVOT) to be between three and eight times more likely to die than real-world patients.
The patient population of the PIVOT study included 731 men with low-, intermediate-, and high-risk prostate cancer. The men in the PIVOT study had an average age of 67 at diagnosis, and the overall mortality was 64 percent over 12.7 years. The PIVOT study found that there was almost no difference in the overall mortality between patients undergoing surgical treatment for prostate cancer and those who opted for observation instead of surgery.
Researchers at Henry Ford Hospital compared the patients of the PIVOT study with:
60,089 men from the Surveillance, Epidemiology, and End Results (SEER; population-based registry) between 2000-2004. 63,303 men from the National Cancer Database (NCDB; hospital-based registry) from 2004-2005. 2,847 men diagnosed with prostate cancer in the Prostate, Lung, Colorectal and Ovarian cancer (PLCO) trial between 1993
Article originally posted at